Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Euro-Med Laboratories Philippines's Revenue for the
three
months ended in Mar. 2026 was ₱1,603 Mil. Euro-Med Laboratories Philippines's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₱1,840 Mil.
Hence, Euro-Med Laboratories Philippines's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.87.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Euro-Med Laboratories Philippines Receivables Turnover Related Terms
Euro-Med Laboratories Philippines Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHS:EURO vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euro-Med Laboratories Philippines (PHS:EURO) has a Receivables Turnover of 0.87 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Euro-Med Laboratories Philippines and its competitors. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #688 out of 949 companies in the Drug Manufacturers industry, placing it in the top 72.5%.
Is Euro-Med Laboratories Philippines' Receivables Turnover too high?
Euro-Med Laboratories Philippines' current Receivables Turnover is 0.87. The Drug Manufacturers industry median Receivables Turnover is 5.07. Euro-Med Laboratories Philippines' value of 0.87 is 82.8% below this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #688 out of 949 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #688 out of 949 companies for Receivables Turnover. This places Euro-Med Laboratories Philippines in the lower half of its industry. The industry median Receivables Turnover is 5.07. Euro-Med Laboratories Philippines' value of 0.87 is 82.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current Receivables Turnover of 0.87 is 82.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current Receivables Turnover is 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.03, compared to a current price of ₱1.03 — trading right at its estimated fair value. The current Receivables Turnover is 0.87 and 82.8% below the Drug Manufacturers industry median of 5.07. Euro-Med Laboratories Philippines' overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current Receivables Turnover is 0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be undervalued.
The current stock price of ₱1.03 is trading 0% below its estimated GF Value™ of ₱1.03.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
Receivables Turnover: 0.87
GF Value™: ₱1.03 vs. price of ₱1.03 (0% below fair value)
Industry Position: 82.8% below the Drug Manufacturers median (#688 of 949)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Business Description
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
86GF Score
Get the complete analysis for PHS:EURO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
